Recent patient studies surrounding the medication Retatrutide , specifically the high-dose formulation branded as ZPHC, reveal a considerable benefit on body mass reduction and associated metabolic factors. Experts anticipate that this dual agonist , influencing both GLP-1 and GIP receptors , has